S&P 500   3,753.59 (-0.39%)
DOW   30,885.07 (-0.13%)
QQQ   297.93 (-2.03%)
AAPL   117.65 (-2.06%)
MSFT   226.91 (+0.08%)
FB   256.26 (-0.54%)
GOOGL   2,032.10 (-0.09%)
TSLA   543.90 (-12.48%)
AMZN   2,885.96 (-3.08%)
NVDA   468.37 (-5.34%)
BABA   228.94 (-0.68%)
CGC   28.20 (-9.06%)
GE   13.18 (-2.87%)
MU   83.59 (-0.88%)
NIO   32.23 (-17.95%)
AMD   74.46 (-4.23%)
T   29.46 (+1.87%)
F   11.68 (-2.10%)
ACB   8.69 (-11.51%)
DIS   183.65 (-2.33%)
BA   214.60 (-4.50%)
NFLX   500.02 (-2.20%)
BAC   36.25 (-0.68%)
S&P 500   3,753.59 (-0.39%)
DOW   30,885.07 (-0.13%)
QQQ   297.93 (-2.03%)
AAPL   117.65 (-2.06%)
MSFT   226.91 (+0.08%)
FB   256.26 (-0.54%)
GOOGL   2,032.10 (-0.09%)
TSLA   543.90 (-12.48%)
AMZN   2,885.96 (-3.08%)
NVDA   468.37 (-5.34%)
BABA   228.94 (-0.68%)
CGC   28.20 (-9.06%)
GE   13.18 (-2.87%)
MU   83.59 (-0.88%)
NIO   32.23 (-17.95%)
AMD   74.46 (-4.23%)
T   29.46 (+1.87%)
F   11.68 (-2.10%)
ACB   8.69 (-11.51%)
DIS   183.65 (-2.33%)
BA   214.60 (-4.50%)
NFLX   500.02 (-2.20%)
BAC   36.25 (-0.68%)
S&P 500   3,753.59 (-0.39%)
DOW   30,885.07 (-0.13%)
QQQ   297.93 (-2.03%)
AAPL   117.65 (-2.06%)
MSFT   226.91 (+0.08%)
FB   256.26 (-0.54%)
GOOGL   2,032.10 (-0.09%)
TSLA   543.90 (-12.48%)
AMZN   2,885.96 (-3.08%)
NVDA   468.37 (-5.34%)
BABA   228.94 (-0.68%)
CGC   28.20 (-9.06%)
GE   13.18 (-2.87%)
MU   83.59 (-0.88%)
NIO   32.23 (-17.95%)
AMD   74.46 (-4.23%)
T   29.46 (+1.87%)
F   11.68 (-2.10%)
ACB   8.69 (-11.51%)
DIS   183.65 (-2.33%)
BA   214.60 (-4.50%)
NFLX   500.02 (-2.20%)
BAC   36.25 (-0.68%)
S&P 500   3,753.59 (-0.39%)
DOW   30,885.07 (-0.13%)
QQQ   297.93 (-2.03%)
AAPL   117.65 (-2.06%)
MSFT   226.91 (+0.08%)
FB   256.26 (-0.54%)
GOOGL   2,032.10 (-0.09%)
TSLA   543.90 (-12.48%)
AMZN   2,885.96 (-3.08%)
NVDA   468.37 (-5.34%)
BABA   228.94 (-0.68%)
CGC   28.20 (-9.06%)
GE   13.18 (-2.87%)
MU   83.59 (-0.88%)
NIO   32.23 (-17.95%)
AMD   74.46 (-4.23%)
T   29.46 (+1.87%)
F   11.68 (-2.10%)
ACB   8.69 (-11.51%)
DIS   183.65 (-2.33%)
BA   214.60 (-4.50%)
NFLX   500.02 (-2.20%)
BAC   36.25 (-0.68%)
Log in
NASDAQ:JYNT

The Joint Stock Forecast, Price & News

$45.94
+1.41 (+3.17 %)
(As of 03/5/2021 11:26 AM ET)
Add
Compare
Today's Range
$44.56
Now: $45.94
$47.16
50-Day Range
$28.24
MA: $35.05
$49.00
52-Week Range
$7.67
Now: $45.94
$50.00
Volume4,357 shs
Average Volume157,929 shs
Market Capitalization$645.04 million
P/E Ratio170.15
Dividend YieldN/A
Beta1.27
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising and the sale of regional developer rights. As of December 31, 2019, the company operated approximately 513 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
The Joint logo

Headlines

The Joint Corp. (JYNT) Q4 Earnings Lag Estimates
March 4, 2021 |  finance.yahoo.com
Joint's Earnings: A Preview
March 3, 2021 |  benzinga.com
Is Joint (NASDAQ:JYNT) Using Too Much Debt?
March 1, 2021 |  finance.yahoo.com
The Joint Corp. to Participate in Upcoming Conferences
February 25, 2021 |  finance.yahoo.com
Buy Alert: The Joint Corp. Stock Is Headed Higher
February 5, 2021 |  finance.yahoo.com
Is The Joint Corp. (JYNT) A Smart Long-Term Buy?
February 1, 2021 |  finance.yahoo.com
The Joint Corp.: Huge Growth Is Still To Come
December 23, 2020 |  seekingalpha.com
Is JYNT A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Lookback: RF Capital’s 2019 Joint Corp (JYNT) Thesis
November 26, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960
Employees150
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.45 million
Cash Flow$0.60 per share
Book Value$0.41 per share

Profitability

Net Income$3.32 million

Miscellaneous

Market Cap$645.04 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

817th out of 1,969 stocks

Patent Owners & Lessors Industry

8th out of 28 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$45.94
+1.41 (+3.17 %)
(As of 03/5/2021 11:26 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











The Joint (NASDAQ:JYNT) Frequently Asked Questions

Is The Joint a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint
or view top-rated stocks.

What stocks does MarketBeat like better than The Joint?

Wall Street analysts have given The Joint a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but The Joint wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were The Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings data on Wednesday, March, 3rd. The company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.14 by $0.58. The Joint had a net margin of 6.89% and a trailing twelve-month return on equity of 51.77%.
View The Joint's earnings history
.

How has The Joint's stock price been impacted by Coronavirus?

The Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JYNT shares have increased by 227.2% and is now trading at $44.53.
View which stocks have been most impacted by COVID-19
.

What guidance has The Joint issued on next quarter's earnings?

The Joint issued an update on its FY 2021 After-Hours earnings guidance on Thursday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73-77 million, compared to the consensus revenue estimate of $72.23 million.

What price target have analysts set for JYNT?

5 brokers have issued twelve-month price objectives for The Joint's stock. Their forecasts range from $35.00 to $54.00. On average, they expect The Joint's stock price to reach $45.60 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts' price targets for The Joint
or view top-rated stocks among Wall Street analysts.

Who are The Joint's key executives?

The Joint's management team includes the following people:
  • Mr. Peter D. Holt, CEO, Pres & Director (Age 62, Pay $666.57k)
  • Jake Singleton, Chief Financial Officer (Age 39, Pay $303.41k)
  • Mr. Jorge Armenteros, VP of Operations
  • Dr. Steven Knauf, Director of Chiropractic & Compliance
  • Mr. Jason Greenwood, VP of Marketing
  • Ms. Amy Karroum, VP of HR
  • Mr. Craig P. Colmar, Sec. (Age 68)
  • Mr. Eric Simon, VP of Franchise Sales & Devel.
  • Mr. David Glover, Regional Developer for West Lake Hills
  • Mr. Richard Matthews, Director of Real Estate Research

What is Peter D. Holt's approval rating as The Joint's CEO?

87 employees have rated The Joint CEO Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of The Joint's key competitors?

What other stocks do shareholders of The Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), salesforce.com (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did The Joint IPO?

(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is The Joint's stock symbol?

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are The Joint's major shareholders?

The Joint's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.14%), Next Century Growth Investors LLC (4.82%), THB Asset Management (2.00%), Royce & Associates LP (1.59%), Morgan Stanley (1.52%) and Northern Trust Corp (1.37%). Company insiders that own The Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Peter D Holt and Ronald V Davella.
View institutional ownership trends for The Joint
.

Which major investors are selling The Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Old Well Partners LLC, Next Century Growth Investors LLC, THB Asset Management, Select Equity Group L.P., Northern Trust Corp, Hsbc Holdings PLC, and STA Wealth Management LLC.
View insider buying and selling activity for The Joint
or view top insider-selling stocks.

Which major investors are buying The Joint stock?

JYNT stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Acuitas Investments LLC, Renaissance Technologies LLC, BlackRock Inc., Ingalls & Snyder LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., and Engineers Gate Manager LP. Company insiders that have bought The Joint stock in the last two years include Bandera Partners Llc, Jake Singleton, James H Amos Jr, and Peter D Holt.
View insider buying and selling activity for The Joint
or or view top insider-buying stocks.

How do I buy shares of The Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $44.53.

How much money does The Joint make?

The Joint has a market capitalization of $625.25 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis.

How many employees does The Joint have?

The Joint employs 150 workers across the globe.

What is The Joint's official website?

The official website for The Joint is www.thejoint.com.

Where are The Joint's headquarters?

The Joint is headquartered at 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260.

How can I contact The Joint?

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.